lornoxicam

Lornoxicam
Systematic (IUPAC) name
	(3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4H-thieno[2,3-e][1,2]thiazin-4-one 1,1-dioxide
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	Not recommended; contraindicated in months 7–9
Legal status	℞ Prescription only
Routes	Oral, parenteral
Pharmacokinetic data
Bioavailability	90–100%
Protein binding	99%
Metabolism	CYP2C9
Half-life	3–4 hours
Excretion	2/3 hepatic, 1/3 renal
Identifiers
ATC code	M01AC05
PubChem	CID 5282204
DrugBank	DB06725
ChemSpider	4445392
UNII	ER09126G7A
KEGG	D01866
ChEBI	CHEBI:31783
Chemical data
Formula	C13H10ClN3O4S2
Mol. mass	371.8192 g/mol
	SMILES CN1C(=C(NC2=CC=CC=N2)O)C(=O)C3=C(S1(=O)=O)C=C(S3)Cl;
(what is this?) (verify);

ロルノキシカム

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/12/05 10:40:53」(JST)

wiki en

[Wiki en表示]

Lornoxicam (INN, or chlortenoxicam; trade name Xefo, among others) is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties. It is available in oral and parenteral formulations.

Indications[edit]

Lornoxicam is used for the treatment of various types of pain, especially resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica, and other inflammations.^[1]

Contraindications[edit]

The drug is contraindicated in patients that must not take other NSAIDs, possible reasons including salicylate sensitivity, gastrointestinal bleeding and bleeding disorders, and severe impairment of heart, liver or kidney function. Lornoxicam is not recommended during pregnancy and breastfeeding and is contraindicated during the last third of pregnancy.^[1]

Lornoxicam has side effects similar to other NSAIDs, most commonly mild ones like gastrointestinal disorders (nausea and diarrhea) and headache. Severe but seldom side effects include bleeding, bronchospasms and the extremely rare Stevens–Johnson syndrome.^[1]

Adverse effects[edit]

Lornoxicam has side effects similar to other NSAIDs, most commonly mild ones like gastrointestinal disorders (nausea and diarrhea) and headache. Severe but seldom side effects include bleeding, bronchospasms and the extremely rare Stevens–Johnson syndrome.^[1]

Interactions[edit]

Interactions with other drugs are typical of NSAIDs. Combination with vitamin K antagonists like warfarin increases the risk of bleeding. Combination with ciclosporin can lead to reduced kidney function, and to acute renal failure in rare cases. Lornoxicam can also increase the adverse effects of lithium, methotrexate and digoxin and its derivatives. The effect of diuretics, ACE inhibitors and angiotensin II receptor antagonists can be reduced, but this is only relevant in patients with special risks like heart failure. As with piroxicam, cimetidine can increase plasma levels but is unlikely to cause relevant interactions.^[2]

References[edit]

^ ^a ^b ^c ^d Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.
^ Klopp, T, ed. (2010). Arzneimittel-Interaktionen (in German) (2010/2011 ed.). Arbeitsgemeinschaft für Pharmazeutische Information. ISBN 978-3-85200-207-1.

English Journal

The potential of immobilized artificial membrane chromatography to predict human oral absorption.

Tsopelas F1, Vallianatou T2, Tsantili-Kakoulidou A2.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2016 Jan 1;81:82-93. doi: 10.1016/j.ejps.2015.09.020. Epub 2015 Oct 19.
The potential of immobilized artificial membrane (IAM) chromatography to estimate human oral absorption (%HOA) was investigated. For this purpose, retention indices on IAM stationary phases reported previously by our group or measured by other authors under similar conditions were used to model %HOA
PMID 26485055

[Comparison of tramadol and lornoxicam in intravenous regional anesthesia: a randomized controlled trial].

Çelik H1, Abdullayev R2, Akçaboy EY3, Baydar M3, Göğüş N4.
Revista brasileira de anestesiologia.Rev Bras Anestesiol.2015 Nov 29. pii: S0034-7094(15)00115-4. doi: 10.1016/j.bjan.2015.11.003. [Epub ahead of print]
BACKGROUND AND OBJECTIVES: Tourniquet pain is one of the major obstacles for intravenous regional anesthesia. We aimed to compare tramadol and lornoxicam used in intravenous regional anesthesia as regards their effects on the quality of anesthesia, tourniquet pain and postoperative pain as well.METH
PMID 26647089

Tri/tetra-block co-polymeric nanocarriers as a potential ocular delivery system of lornoxicam: in-vitro characterization, and in-vivo estimation of corneal permeation.

Salama AH1, Shamma RN2.
International journal of pharmaceutics.Int J Pharm.2015 Aug 15;492(1-2):28-39. doi: 10.1016/j.ijpharm.2015.07.010. Epub 2015 Jul 4.
Polymeric micelles that can deliver drug to intended sites of the eye have attracted much scientific attention recently. The aim of this study was to evaluate the aqueous-based formulation of drug-loaded polymeric micelles that hold significant promise for ophthalmic drug delivery. This study invest
PMID 26151106

Japanese Journal

Design of Meloxicam and Lornoxicam Transdermal Patches: Preparation, Physical Characterization, ex Vivo and in Vivo Studies

Yener Gülgün,Üner Melike,Gönüllü Ümit,Yildirim Sinem,Kiliç Pınar,Aslan Serap Sağlik,Barla Aslı
CHEMICAL & PHARMACEUTICAL BULLETIN 58(11), 1466-1473, 2010
… Transdermal patches of meloxicam (MX) and lornoxicam (LX) were aimed to be prepared in order to overcome their side effects by oral application. …
NAID 130000405660